Visceral adiposity index: an indicator of adipose tissue dysfunction

Marco Calogero Amato, Carla Giordano, Marco Calogero Amato, Carla Giordano

Abstract

The Visceral Adiposity Index (VAI) has recently proven to be an indicator of adipose distribution and function that indirectly expresses cardiometabolic risk. In addition, VAI has been proposed as a useful tool for early detection of a condition of cardiometabolic risk before it develops into an overt metabolic syndrome. The application of the VAI in particular populations of patients (women with polycystic ovary syndrome, patients with acromegaly, patients with NAFLD/NASH, patients with HCV hepatitis, patients with type 2 diabetes, and general population) has produced interesting results, which have led to the hypothesis that the VAI could be considered a marker of adipose tissue dysfunction. Unfortunately, in some cases, on the same patient population, there is conflicting evidence. We think that this could be mainly due to a lack of knowledge of the application limits of the index, on the part of various authors, and to having applied the VAI in non-Caucasian populations. Future prospective studies could certainly better define the possible usefulness of the VAI as a predictor of cardiometabolic risk.

Figures

Figure 1
Figure 1
Linear relationship observed between BMI and WC in 315 primary care patients, with BMI between 20 and 30 Kg/m2 and age 43.46 ± 14.30 years (range 19–83), selected because of absence of diabetes mellitus or FPG ≥ 5.6 mmol/L, high blood pressure, dyslipidemia, metabolic syndrome and cardiovascular disease (CVD). A model of adipose distribution (MOAD) was created based on this gender-specific linear equation. Taken from Amato et al. [8].

References

    1. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. The American Journal of Clinical Nutrition. 2000;72(3):694–701.
    1. .
    1. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. The Journal of the American Medical Association. 2005;293(15):1861–1867.
    1. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. The Lancet. 2006;368(9536):666–678.
    1. Franzosi MG. Should we continue to use BMI as a cardiovascular risk factor? The Lancet. 2006;368(9536):624–625.
    1. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438)(937):p. 952.
    1. Yusuf S, Hawken S, Ôunpuu S, et al. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. The Lancet. 2005;366(9497):1640–1649.
    1. Amato MC, Giordano C, Galia M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–922.
    1. Knowles KM, Paiva LL, Sanchez SE, et al. Waist circumference, body mass index, and other measures of adiposity in predicting cardiovascular disease risk factors among peruvian adults. International Journal of Hypertension. 2011;2011:10 pages.931402
    1. Bozorgmanesh M, Hadaegh F, Azizi F. Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 Diabetes. Lipids in Health and Disease. 2011;10, article 88
    1. Al-Daghri NM, Al-Attas OS, Alokail MS, et al. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. European Journal of Clinical Investigation. 2013;43(2):183–189.
    1. Du T, Sun X, Huo R, Yu X. Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: the China health and nutrition survey 2009. International Journal of Obesity. 2013
    1. Stepien M, Stepien A, Banach M, et al. New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis. Angiology. 2014;65(4):333–342.
    1. Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity. 2013;21(8):1690–1694.
    1. Stepien M, Stepien A, Wlazel RN, et al. Predictors of insulin resistance in patients with obesity: a pilot study. Angiology. 2014;65(1):22–30.
    1. Zhang X, Shu XO, Li H, et al. Visceral adiposity and risk of coronary heart disease in relatively lean Chinese adults. International Journal of Cardiology. 2013;168(3):2141–2145.
    1. Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids in Health and Disease. 2011;10, article 183
    1. Mohammadreza B, Farzad H, Davoud K, Fereidoun A. Prognostic significance of the complex “visceral adiposity index” versus simple anthropometric measures: Tehran lipid and glucose study. Cardiovascular Diabetology. 2012;11(article 20)
    1. Elisha B, Messier V, Karelis A, et al. The visceral adiposity index: relationship with cardiometabolic risk factors in obese and overweight postmenopausal women—a MONET group study. Applied Physiology, Nutrition, and Metabolism. 2013;38(8):892–899.
    1. Li Y, Liu L, Wang B, Wang J, Chen D. Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. Clinics and Research in Hepatology and Gastroenterology. 2014;38(1):46–54.
    1. Li Y, Liu L, Wang B, Chen D. Letter: is visceral adiposity index a predictor of liver histology in patients with non-alcoholic fatty liver disease? Alimentary Pharmacology and Therapeutics. 2013;37(5):p. 583.
    1. Musso G, Cassader M, de Michieli F, Rosina F, Orlandi F, Gambino R. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology. 2012;56(3):933–942.
    1. Vongsuvanh R, George J, McLeod D, van der Poorten D. Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2012;57(2):392–398.
    1. Musso G, Cassader M, Gambino R. Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. Hepatology. 56(2):788–789.
    1. Petta S, Amato MC, Di Marco V, et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2012;35(2):238–247.
    1. Amato MC, Giordano C. Clinical indications and proper use of visceral adiposity index. Nutrition, Metabolism & Cardiovascular Diseases. 2013;23(8):e31–e32.
    1. Petta S, Amato M, Cabibi D, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology. 2010;52(5):1543–1552.
    1. Ticehurst JR, Hamzeh FM, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. Journal of Clinical Microbiology. 2007;45(8):2426–2433.
    1. Chen W, Wong T, Tomlinson G, Krahn M, Heathcote EJ. Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. Journal of Hepatology. 2008;49(5):711–717.
    1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews. 1997;18(6):774–800.
    1. Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction. 2013;28(3):777–784.
    1. Després JP. What is “metabolically healthy obesity”? From epidemiology to pathophysiological insights. The Journal of Clinical Endocrinology and Metabolism. 2012;97(7):2283–2285.
    1. Amato MC, Verghi M, Galluzzo A, Giordano C. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Human Reproduction. 2011;26(6):1486–1494.
    1. Androulakis II, Kandaraki E, Christakou C, et al. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clinical Endocrinology. 2014
    1. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. The Journal of Clinical Endocrinology and Metabolism. 2010;95(5):2038–2049.
    1. Amato MC, Guarnotta V, Forti D, Donatelli M, Dolcimascolo S, Giordano C. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment. Human Reproduction. 2013;28(7):1919–1928.
    1. Katznelson L. Alterations in body composition in acromegaly. Pituitary. 2009;12(2):136–142.
    1. Freda PU, Shen W, Heymsfield SB, et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. The Journal of Clinical Endocrinology and Metabolism. 2008;93(6):2334–2343.
    1. Zhao YF, Feng DD, Chen C. Contribution of adipocyte-derived factors to beta-cell dysfunction in diabetes. International Journal of Biochemistry and Cell Biology. 2006;38(5-6):804–819.
    1. Ciresi A, Amato MC, Pivonello R, et al. The metabolic profile in active acromegaly is gender-specific. The Journal of Clinical Endocrinology and Metabolism. 2013;98(1):E51–E59.
    1. Ciresi A, Amato MC, Pizzolanti G, Galluzzo CG. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. The Journal of Clinical Endocrinology and Metabolism. 2012;97(8):2907–2915.
    1. Naliato ECO, Violante AHD, Gaccione M, et al. Body fat in men with prolactinoma. Journal of Endocrinological Investigation. 2008;31(11):985–990.
    1. Naliato ECO, Violante AH, Caldas D, et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clinical Endocrinology. 2007;67(6):845–852.
    1. Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clinical Endocrinology. 2013;79(6):845–852.
    1. Auriemma RS, Granieri L, Galdiero M, et al. Effect of chronic treatment with cabergoline on metabolic parameters in patients with prolactinomas. Neuroendocrinology. 2013;98(4):299–310.
    1. Giordano C, Guarnotta V, Pivonello R, et al. Is diabetes in cushing syndrome only a consequence of hypercortisolism? European Journal of Endocrinology. 2013;170(2):311–319.
    1. Mazzuca E, Battaglia S, Marrone O, et al. Gender-specific anthropometric markers of adiposity, metabolic syndrome and visceral adiposity index (VAI) in patients with obstructive sleep apnea. Journal of Sleep Research. 2014;23(1):13–21.
    1. Celik A, Saricicek E, Saricicek V, et al. Effect of Ramadan fasting on serum concentration of apelin-13 and new obesity indices in healthy adult men. Medical Science Monitor. 2014;20:337–342.
    1. Al-Daghri NM, Al-Attas OS, Alokail M, et al. Does visceral adiposity index signify early metabolic risk in children and adolescents? Association with insulin resistance, adipokines, and subclinical inflammation. Pediatric Research. 2014;75(3):459–463.
    1. Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS ONE. 2014;9(3)e91969

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere